Paysign, Inc. to Sponsor the 2024 Gene Therapy for Rare Disorders Conference March 26-29
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
In keeping with their commitment to patient affordability and access, Paysign is sponsoring the annual event as an Exhibition Partner. The conference is the gene therapy industry’s leading event where key figures, service providers, payers and regulators discuss insights to the crucial challenges that face these programs today.
"We are thrilled to add this event to our annual schedule of sponsorships and to provide much-needed representation for patient affordability solutions that tackle the biggest issues facing access to gene therapy for rare disorders,” said Matthew Turner, President, Patient Affordability at Paysign.
Stop by and see the Paysign team at their booth to network and gain fundamental insights on how to mitigate barriers to patient access. To learn more about Paysign’s patient affordability solutions, visit paysign.com/rx.
Visit the Gene Therapy for Rare Disorders conference website to learn more and register for the event.
About Paysign
Paysign, Inc. is a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers and government institutions. Founded in 2001 and headquartered in southern
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312706790/en/
Investor Relations
ir@paysign.com
888.522.4853
paysign.com/investors
Media Relations
Alicia Ches
702.749.7257
pr@paysign.com
Source: Paysign, Inc.